Youth e-cigarette use in the United States is an epidemic, Food and Drug Administration (FDA) Commissioner Scott Gottlieb said Wednesday. He announced new steps the agency is taking to prevent youth vaping.
The FDA will stop sales of flavored e-cigarettes if major manufacturers cannot prove they are doing enough to keep them out of the hands of children and teens, USA Today reports. The agency is giving manufacturers 60 days to submit plans to prevent youth e-cigarette use. If the FDA does not approve the plans, it could order their products off the market.
Full story at drugfree.org
The Food and Drug Administration (FDA) announced a major crackdown on the vaping industry, particularly on the trendy Juul devices, aimed at curbing sales to young people, The New York Times reports.
Vaping is the act of inhaling and exhaling the aerosol, often referred to as vapor, produced by an e-cigarette or similar device and has become more popular among teens than regular cigarettes. One of the slang terms for vaping, known as JUULing (“jeweling”), comes from the JUUL brand device that looks like a flash drive, as opposed to a regular e-cigarette.
The FDA started an undercover sting operation this month targeting retailers of Juuls, including gas stations, convenience stores and several online retailers. As part of the crackdown, the agency demanded that Juul Labs turn over company documents focused on the sales and research behind its products. The FDA is looking to determine whether Juul is intentionally marketing to teenagers and youth, despite the company’s statements to the contrary.
Full story at drugfree.org
The use of nicotine patches, gum, lozenges, inhalers or nasal sprays — together called “nicotine replacement therapy,” or NRT — came into play in 1984 as prescription medicine, which when combined with counseling, helped smokers quit. But in 1996, at the urging of pharmaceutical companies, the U.S. Food and Drug Administration (FDA) allowed those products to be sold over-the-counter.
Now, a new study conducted by scientists at UC San Francisco reports that tobacco companies have known for decades that, without counseling, NRT hardly ever works, and that consumers often use it to complement smoking. This insight from the formerly secret industry documents known as the “Tobacco Papers” reveals why companies that once viewed nicotine patches and gum as a threat to their cigarette sales now embrace them as a business opportunity, the researchers said.
Full story at Science Daily
The U.S. Senate on Wednesday passed the 21st Century Cures Act, which includes $1 billion in new funding to prevent and treat opioid addiction. The House approved the measure last week.
The legislation includes funding for cancer research and mental health treatment, and will help the Food and Drug Administration speed up drug approvals. The measure also aims to improve the use of technology in medicine. The legislation passed 94 to 5, according to The New York Times.
Full story of prevention and treatment of opioid addiction bill at drugfree.org
The Food and Drug Administration (FDA) will determine whether naloxone devices distributed in communities should contain a standard dose of the opioid overdose antidote, according to U.S. News & World Report.
Drug companies that make naloxone devices do not agree on how much naloxone should be administered following an opioid overdose, the article notes. The outcome of a meeting this week between the FDA and naloxone makers could change the drug’s pricing and availability. The average price of naloxone has risen from $1 a dose a decade ago to $40 a dose today.
Full story of FDA on naxolone devices and standard doses at drugfree.org